WO2006125450A1 - Rectal and vaginal suppositories containing misoprostol - Google Patents

Rectal and vaginal suppositories containing misoprostol Download PDF

Info

Publication number
WO2006125450A1
WO2006125450A1 PCT/EG2005/000033 EG2005000033W WO2006125450A1 WO 2006125450 A1 WO2006125450 A1 WO 2006125450A1 EG 2005000033 W EG2005000033 W EG 2005000033W WO 2006125450 A1 WO2006125450 A1 WO 2006125450A1
Authority
WO
WIPO (PCT)
Prior art keywords
misoprostol
vaginally
tablets
rectally
rectal
Prior art date
Application number
PCT/EG2005/000033
Other languages
French (fr)
Inventor
Atef Mohammed Mostafa Darwish
Original Assignee
Atef Mohammed Mostafa Darwish
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atef Mohammed Mostafa Darwish filed Critical Atef Mohammed Mostafa Darwish
Publication of WO2006125450A1 publication Critical patent/WO2006125450A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Definitions

  • Misooprostol is considered a basic drug used in Obstetric practice in controlling postpartum and post-abortive bleeding, and induction of labor or abortion whenever indicated. Its basic route of administration is orally. However, the commercial tablets were tested via the oral cavity ( sublingually ), rectally or vaginally.
  • the drug is prepared in a suppository form ( rectal and vaginal ) to be convenient for the patients. Moreover, some additives to enhance absorption as pluronics were added. Using bioadhesive technology is also included to facilitate maximal drug release and absorption.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Misoprostol is commonly used in obstetric practice for controlling post-partum and post-abortive bleeding, and inducing labor or abortion whenever indicated. Commonly, misoprostol is administered orally. Tests have been carried out to study the behaviour of the commercial tablets when administered sublingually, rectally or vaginally. However, the application of said tablets, either vaginally or rectally, in their current form is not easy, as the tablets are designed for oral use. The present invention concerns misoprostol-containing suppositories, which are more convenient, if used rectally resp. vaginally. Additionally, the suppositories contain at least one poloxamer to enhance absorption and at least one bioadhesive compound.

Description

Rectal and Vaginal Suppositories Containing Misoprostol
Technical Field:
Misooprostol is considered a basic drug used in Obstetric practice in controlling postpartum and post-abortive bleeding, and induction of labor or abortion whenever indicated. Its basic route of administration is orally. However, the commercial tablets were tested via the oral cavity ( sublingually ), rectally or vaginally.
Background:
Usage of the tablets in their current form vaginally or rectally is not perfect as these tablets are designed for oral use.
Disclosure of the invention:
In this current patent, the drug is prepared in a suppository form ( rectal and vaginal ) to be convenient for the patients. Moreover, some additives to enhance absorption as pluronics were added. Using bioadhesive technology is also included to facilitate maximal drug release and absorption.
Best mode for carrying out the invention:
Manufacturing this new foπnulation in a suppository form to be suited for vaginal as well as rectal application.
Industrial applicability:
It is easily manufactured in a suppository form.

Claims

Claims
- Creation of vaginal and rectal suppositories containing misoprostol - Adding bioadhesive substances and pluronics to the active ingredient
PCT/EG2005/000033 2005-05-26 2005-10-01 Rectal and vaginal suppositories containing misoprostol WO2006125450A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005050255 2005-05-26
EG2005050255 2005-05-26

Publications (1)

Publication Number Publication Date
WO2006125450A1 true WO2006125450A1 (en) 2006-11-30

Family

ID=37451640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2005/000033 WO2006125450A1 (en) 2005-05-26 2005-10-01 Rectal and vaginal suppositories containing misoprostol

Country Status (1)

Country Link
WO (1) WO2006125450A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2965750A1 (en) 2014-07-11 2016-01-13 Azanta A/S Misoprostol dispersible tablet
WO2016004960A2 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
RU2580165C1 (en) * 2015-04-03 2016-04-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Омская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМА Минздрава России) Method for termination of pregnancy in later stages on medical indications
RU2654707C1 (en) * 2016-12-08 2018-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Combined method of induced abortion in the second trimester on medical indications
US10688072B2 (en) 2014-07-11 2020-06-23 Azanta Danmark A/S Misoprostol dispersible tablet

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0864326A2 (en) * 1997-03-12 1998-09-16 Knoll Ag Multiphasic preparation comprising an active agent
DE19812688A1 (en) * 1998-03-23 1999-09-30 Basf Ag Solid dosage forms useful for slow release of drugs, fragrances, plant-treating agents, animal feed additives and food additives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0864326A2 (en) * 1997-03-12 1998-09-16 Knoll Ag Multiphasic preparation comprising an active agent
DE19812688A1 (en) * 1998-03-23 1999-09-30 Basf Ag Solid dosage forms useful for slow release of drugs, fragrances, plant-treating agents, animal feed additives and food additives

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2965750A1 (en) 2014-07-11 2016-01-13 Azanta A/S Misoprostol dispersible tablet
WO2016004960A2 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
US10688072B2 (en) 2014-07-11 2020-06-23 Azanta Danmark A/S Misoprostol dispersible tablet
US12005041B2 (en) 2014-07-11 2024-06-11 Azanta Danmark A/S Misoprostol dispersible tablet
RU2580165C1 (en) * 2015-04-03 2016-04-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Омская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОмГМА Минздрава России) Method for termination of pregnancy in later stages on medical indications
RU2654707C1 (en) * 2016-12-08 2018-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Combined method of induced abortion in the second trimester on medical indications

Similar Documents

Publication Publication Date Title
ATE350018T1 (en) SOLID ORAL DOSAGE FORMS WITH SUSTAINED RELEASE AND HIGH MECHANICAL STABILITY
WO2006125450A1 (en) Rectal and vaginal suppositories containing misoprostol
UY29527A1 (en) PHARMACCUTIC COMPOSITION CONTAINING GESTRGENS AND / OR ESTRNGENS AND 5-METHYL - (6S) - TETRHYDROPHOLATE.
DE60138468D1 (en) CYANOPHENOXY CARBOXYLIC ACIDS AND COMPOSITIONS FOR THE RELEASE OF ACTIVE SUBSTANCES
PE20010298A1 (en) COMPOSITION FOR ORAL DOSAGE, INSTANTLY DISSOLVING
IN2012DN06436A (en)
UY30462A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROPHOLIC ACID.
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
AR035637A1 (en) BETAMIMETICOS OF LONG ACTION, PROCEDURE FOR ITS PREPARATION AND ITS EMPLOYMENT AS MEDICATIONS
NZ602538A (en) Thermogelling anaesthetic compositions
MA28358A1 (en) INHIBITORS OF HIV INTEGRASE
MA28519B1 (en) INHIBITORS OF HIV INTEGRASE
MY148125A (en) Compounds
TR201908600T4 (en) (11.beta., 17.beta.) - 17-hydroxy-11- [4- (methylsulfonyl) phenyl] -17- (pentafluoromethyl) estra-4,9-dien-3-one for the treatment of diseases.
GEP20074224B (en) Pharmaceutical compositions of sertaconazole for vaginal use
DE60234725D1 (en) Vaginally administrable composition for the treatment of uterine dysrhythmia
RU2009120990A (en) APPLICATION OF TESTOSTERONE AND 5-HT1A AGONIST FOR TREATMENT OF SEXUAL DYSFUNCTION
DE502006007702D1 (en) TABLETIC RETARD PREPARATION CONTAINING CINNARIC ACID AND DIMENHYDRINATE AGAINST DIFFICULTY
ME00549B (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
ITMI20031640A1 (en) BASE FOR BIOADHESIVE GEL.
AR035064A1 (en) 3- (1-METHYL-3-INDOLIL) -4- (1-METHYL-6-NITRO-3-INDOLIL) -1H-PIRROL-2,5-DIONA, AMORPHALLY, PROCESSES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT THE UNDERSTAND AND USE OF SUCH COMPOUND IN THE MANUFACTURE OF MEDICINES
EA201501011A1 (en) DOSED FORM ANTAGONIST PROGESTERONE RECEPTOR
UY27596A1 (en) ORAL FORMULATION OF PURISIMATE FLUDARA WITH RAPID RELEASE OF INGREDIENT
WO2006105741A3 (en) Topical pharmaceutical formulation containing nimesulide
JP2006160607A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 05787819

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112 (1) EPC, EPO FORM 1205A DATED 22.02.08.